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INTRODUCTION 
 
Ageing is associated with changes in autonomic 
nervous system function and is characterized by 
increases in sympathetic and decreases in 
parasympathetic nervous activity [1, 2]. Such autonomic 
changes can be detrimental to heart function, emotion, 
mood and gut function, and may play a role in a range 
of conditions that increase in prevalence with ageing, 
including heart failure [3, 4], hypertension [5] and 
depression [6, 7]. These conditions are typically 
accompanied with increases in medication consumption 
and decreases in quality of life (QoL). Preventing or 
reducing age-related changes in autonomic balance may 
therefore improve health in older individuals, as well as 
increase their independence, QoL and mood 
(particularly depression). Potential benefits include 
reduced risk of mortality and reductions in the need for 
medication and/or hospitalisation. 
 
Interventions which aim to boost parasympathetic 
activity and/or decrease sympathetic activity include 
vagus nerve stimulation (VNS) and transcutaneous 
vagal nerve stimulation (tVNS). VNS involves 
surgically implanting an electrode around the cervical 
vagus nerve and a generator unit in the thoracic wall 
[8]. However, due to its invasive nature, technical 
complications and side-effects e.g. pain, coughing, 
hoarseness of voice [8, 9], potentially simpler and safer 
therapies are of interest.  
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ABSTRACT 
 
Ageing is associated with attenuated autonomic function. Transcutaneous vagal nerve stimulation (tVNS) 
improved autonomic function in healthy young participants. We therefore investigated the effects of a single 
session of tVNS (studies 1 and 2) and tVNS administered daily for two weeks (study 3) in volunteers aged ≥ 55 
years. tVNS was performed using modified surface electrodes on the tragus and connected to a transcutaneous 
electrical nerve stimulation (TENS) machine. Study 1: participants (n=14) received a single session of tVNS and 
sham. Study 2: all participants (n=51) underwent a single session of tVNS. Study 3: participants (n=29) received 
daily tVNS for two weeks. Heart rate variability and baroreflex sensitivity were derived. Quality of life (QoL), 
mood and sleep were assessed in study 3. tVNS promoted increases in measures of vagal tone and was 
associated with greater increases in baroreflex sensitivity than sham. Two weeks of daily tVNS improved 
measures of autonomic function, and some aspects of QoL, mood and sleep. Importantly, findings showed that 
improvements in measures of autonomic balance were more pronounced in participants with greater baseline 
sympathetic prevalence. This suggests it may be possible to identify individuals who are likely to encounter 
significant benefits from tVNS.  
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tVNS is a simple, non-invasive and inexpensive therapy 
that involves stimulating the auricular branch of the 
vagus nerve (ABVN) at outer parts of the ear, 
conferring autonomic benefits in healthy volunteers 
[10]. For instance, [11] revealed that 15 minutes of 
tVNS administered to the tragus significantly increased 
heart rate variability (HRV), at least partly through 
reductions in sympathetic nerve activity. An increase in 
parasympathetic activity is also likely, since tVNS 
increases spontaneous cardiac baroreflex sensitivity 
(BRS) even in healthy young males [12]. Baseline HRV 
decreases with increasing age [13-16] and since tVNS 
induces larger increases in HRV in participants with 
lower starting HRV [11], tVNS could be particularly 
effective in older compared to younger participants. We 
therefore investigated if tVNS could ameliorate age-
related changes in autonomic function. 
 
We report on three studies into the effects of tVNS in 
participants aged ≥ 55 years. In the first study we 
compared the effects of acute tVNS on cardiovascular 
autonomic function with the effects of sham stimulation 
by measuring HRV and BRS. Since not all participants 
responded to tVNS, we examined if it was possible to 
identify potential tVNS responders from baseline 
parameters. In the second study, we explored the effects 
of acute tVNS on autonomic function in the same age 
group by expanding the sample. The final study aimed 
to examine how daily tVNS (a 15-minute session 
administered once daily for two weeks) impacted 
measures of autonomic function, as well as health-
related QoL, mood and sleep.  
 
RESULTS 
 
Study 1 
 
14 participants aged ≥ 55 years with no previous 
medical history of hypertension, cardiac disease, 
diabetes mellitus or epilepsy were enrolled on the study 
(see Supplementary Table 1). 
 
tVNS vs. sham effects on cardiac baroreflex and 
HRV  
 
Change in baroreflex sensitivity (BRS) between 
baseline and tVNS significantly differed between the 
tVNS and sham visits (p = 0.028): there was a 
significantly greater increase in BRS during the tVNS 
visit (3.28 ± 0.59 ms/mmHg) compared to the sham 
visit (0.81 ± 0.68 ms/mmHg). Baseline heart rate 
variability (HRV), measured as ratio of LF/HF power, 
significantly predicted response to tVNS (R2 = 0.772, p 
< 0.001, see Figure 1), where higher resting LF/HF ratio 
was associated with greater decreases during tVNS. 
Removing the potential outlier with a baseline LF/HF 
ratio > 5 had a slight impact on the regression (R2 = 
0.480, p = 0.009). This HRV analysis revealed that the 
LF/HF ratio response of four participants was greater 
than a 20% increase, corresponding to a definition of 
responders previously applied [11]. 
 
Study 2 
 
Fifty-one healthy participants aged ≥ 55 years were 
recruited. Two participants were excluded due to the 
presence of > 3 ectopic heartbeats in any given five-
minute period (n = 1 female). A further participant was 
excluded due to a respiration rate < 10 breaths per 
minute (n = 1 male). Characteristics of the final sample 
for study 2 are presented in Supplementary Table 2. 
 
tVNS significantly increased heart rate variability in 
≥ 55-year-old participants 
 
Analysis of the whole cohort in study 2 revealed that 
measures considered to reflect vagal activity were 
significantly higher during tVNS (RMSSD: p = 0.007; 
pRR50: p = 0.005; SD1: p = 0.007; BRS: p = 0.001) and 
recovery (HF power: p = 0.008) compared to baseline 
(see Supplementary Table 3). 
 
In addition, LF power, SD2 and nSD2, representing 
combined sympathetic and parasympathetic influences 
on the heart, were significantly higher during tVNS (p = 
0.007, p < 0.001 and p = 0.005 respectively) and 
recovery (p = 0.001, p < 0.001 and p = 0.002 
respectively).  
 
 
Figure 1. Baseline LF/HF ratio significantly predicted response 
(change) to tVNS. 
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Measures of overall variability were significantly 
impacted by tVNS. Total power, mean RR interval, Δ 
RR, SDRR and S were significantly higher during tVNS 
(all p < 0.001) and recovery (all p < 0.001) compared to 
baseline. 
 
Response to tVNS was predicted by baseline LF/HF 
ratio 
 
Linear regression revealed a significant prediction 
between baseline LF/HF ratio and Δ LF/HF ratio such 
that a higher LF/HF ratio predicted a greater decrease to 
tVNS (R2 = 0.498, p < 0.001, Figure 2) in the cohort of 
51 participants.  
 
tVNS responders showed shifts towards 
parasympathetic prevalence during tVNS 
 
Using the response definition employed in study 1 (20% 
decrease in LF/HF ratio), 16 responders and 32 non-
responders were identified. Further analysis revealed 
that baseline measures reflecting parasympathetic 
activity (HF power: p = 0.013; nuHF: p = 0.001; 
RMSSD: p = 0.029; SD1: p = 0.029; nSD1: p = 0.029 
and BRS: p = 0.011) and overall variability in HR (S: p 
= 0.034) were significantly lower in responders 
compared to non-responders (see Supplementary Table 
4). In addition, measures of baseline sympathovagal 
outflow (nuLF: p = 0.001) and sympathovagal balance 
(LF/HF ratio: p < 0.001) were significantly higher in 
responders compared to non-responders. This suggests 
that at rest, responders had significantly lower vagal 
tone and greater sympathetic prevalence compared to 
non-responders. There were no statistically significant 
differences in demographic information between 
responders and non-responders (see Supplementary 
Table 5). 
 
Study 3 
 
The characteristics of the final sample of 26 participants 
are presented in Table 1. 
 
Daily tVNS sessions improved baseline measures of 
autonomic function 
 
Baseline Δ RR, an indicator of cardiac vagal tone, (R2 = 
0.330, p = 0.002) and BRS (R2 = 0.330, p = 0.002) 
during visit 1 significantly predicted change during 
baseline at visit 2: the lower the baseline Δ RR and BRS 
in visit 1, the greater the increase in baseline Δ RR and 
BRS at visit 2 (Figure 3). 
 
 
Figure 2. Baseline LF/HF ratio significantly predicted change 
in LF/HF during tVNS (Δ LF/HF ratio). 
 
Table 1. Summary of characteristics of the final sample of study 3. 
Final sample size (n) 26 
Gender (frequency of males) 9 
Age (yrs.) 64.12 (1.02) 
BMI (kg/m2) 28.07 (1.28) 
Baseline systolic blood pressure (SBP, mmHg) 123.67 (3.14) 
Baseline diastolic blood pressure (DBP, mmHg) 81.85 (1.92) 
Baseline mean arterial pressure (MAP, mmHg) 95.79 (2.22) 
 
 
www.aging-us.com 4839 AGING 
Measures of autonomic tone after two weeks of daily 
tVNS 
 
Two-way repeated measure ANOVAs revealed that 
measures of vagal tone: RMSSD, pRR50, SD1 and 
nSD1, were significantly higher during visit 2 compared 
to visit 1 when values during all three recordings 
(baseline, tVNS, recovery) were combined across each 
visit (main effect of visit: RMSSD, p = 0.016; pRR50, p 
= 0.010; SD1, p = 0.016; nSD1, p = 0.022, see 
Supplementary Table 6). Also, HF power tended to be 
higher during visit 2 than during visit 1 (main effect of 
visit: p = 0.051). Similarly, measures reflecting short 
and long terms variations in HR, total power, SDRR, 
SD2 and S were significantly greater during visit 2 than 
visit 1 (main effect of visit: total power, p = 0.046; 
SDRR, p = 0.024; SD2, p = 0.035 and S, p = 0.012). 
 
Two-way repeated measure ANOVAs also showed that 
total power (p = 0.010), SDRR (p = 0.001), SD2 (p = 
0.001), S (p = 0.017), mean RR interval (p < 0.001) and 
nSD2 (p = 0.001) were significantly higher during 
tVNS compared to baseline (main effect of condition). 
Some of these changes persisted into the recovery 
period: total power (p = 0.034), SDRR (p = 0.008), 
SD2 (p = 0.004), mean RR interval (p = 0.005) and 
nSD2 (p = 0.008) were significantly higher during 
recovery than in baseline. LF power was also 
significantly higher during tVNS compared to baseline 
(p = 0.033, main effect of recording: p = 0.039, see 
Supplementary Table 7). 
 
A significant interaction effect transpired for Δ RR (p = 
0.036, see Figure 4). Further analysis revealed that Δ 
 
 
Figure 3. Visit 1 baseline Δ RR (A) and BRS (B) significantly predicted change at visit 2 baseline, where lower baseline Δ RR (A) and 
BRS (B) in visit 1 were associated with greater increases in baseline Δ RR (A) and BRS (B) in visit 2. In A, Δ Δ RR reflects the difference 
between maximum and minimum RR intervals (Δ RR) between visit 1 baseline and visit 2 baseline. In B, Δ BRS reflects the difference 
in BRS between visit 1 baseline and visit 2 baseline. 
 
 
 
Figure 4. Δ RR significantly differed both within and between 
the two visits (p = 0.036); * = significantly different to visit 2 
recovery. 
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RR was significantly higher during visit 2 recovery 
compared to visit 1 recovery (p = 0.001). Furthermore, 
in visit 2 only, Δ RR was significantly greater during 
recovery than baseline (p = 0.024). 
 
Response to tVNS in both visits was predicted by 
baseline LF/HF ratio 
 
Linear regressions revealed a statistically significant 
prediction between baseline LF/HF ratio and change 
during tVNS in visits 1 (R2 = 0.352, p = 0.001) and 2 
(R2 = 0.697, p < 0.001). As illustrated in Figure 5, 
higher baseline LF/HF ratio values were associated with 
greater decreases in LF/HF ratio during tVNS in both 
visits. 
 
Responders had higher baseline sympathetic 
prevalence than non-responders 
 
Nine responders and 17 non-responders were identified 
in visit 1. Responders had significantly lower indicators 
of vagal tone at baseline in visit 1 than non-responders: 
HF power (p = 0.034), nSD1 (p = 0.039) and BRS (p = 
0.036, see Supplementary Table 8). In addition, 
responders had significantly higher sympathetic 
prevalence during visit 1 baseline than non-responders: 
SD2 (p = 0.028) and nSD2 (p = 0.036), and 
significantly lower overall variability in HR during visit 
1 baseline compared to non-responders: SDRR (p = 
0.038) and S (p = 0.039). There were no significant 
differences in demographic, health-related QoL, mood 
or sleep characteristics between responders and non-
responders (p > 0.05). 
 
Interestingly, two-thirds (n = 6) of responders 
encountered a lowering of their baseline LF/HF ratio 
after two weeks of daily tVNS (see Figure 6, visit 1  
 
 
Figure 5. Baseline LF/HF ratio in visits 1 (A) and 2 (B) significantly predicted change in LF/HF ratio between baseline and tVNS. Δ 
refers to the differences between baseline and tVNS. 
 
 
 
Figure 6. Baseline LF/HF ratio reduced after 2 weeks of daily 
tVNS in six responders with three showing an increase in 
baseline LF/HF ratio following the daily tVNS (indicated by the 
blue boxes). 
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mean: 2.68, SEM: 0.87; visit 2 mean: 0.79, SEM: 0.29, p 
= 0.028). However, there were three responders whose 
baseline LF/HF ratio increased between visit 1 (mean: 
1.58, SEM: 0.54) and visit 2 (mean: 2.69, SEM: 0.95, 
see Figure 6), although all still responded in visit 2.  
For the group of responders in visit 1 (n = 9), LF/HF 
ratio was significantly lower during tVNS (0.95 ± 0.18) 
compared to baseline (2.32 ± 0.59, p < 0.001) and 
recovery (1.46 ± 0.27, p = 0.029, Friedman’s test: p = 
0.001, see Figure 7a). But, in visit 2, LF/HF ratio did 
not significantly differ between baseline, tVNS and 
recovery for the whole group of responders (p > 0.05, 
see Figure 7b), possibly due to slight decreases in 
baseline LF/HF ratio. 
 
Some non-responders (n = 7) even encountered a 
lowering of their baseline LF/HF ratio after two weeks 
of daily tVNS (visit 1 mean: 1.26, SEM: 0.39; visit 2 
mean: 0.63, SEM: 0.16, p = 0.018, see Figure 8). Seven 
of these participants then became responders to tVNS in 
visit 2. In contrast, some non-responders (n = 10) 
showed increases in baseline LF/HF ratio after two 
weeks of daily tVNS (visit 1 mean: 1.30, SEM: 0.35; 
visit 2 mean: 2.61, SEM: 0.80, p = 0.009) all of whom 
remained non-responders at visit 2. 
 
For the group of visit 1 non-responders (n = 17), LF/HF 
ratio did not significantly differ between baseline, tVNS 
or recovery in visits 1 or 2 (p > 0.05, see Figure 9), 
probably due to low initial values.  
 
Daily tVNS also improved health-related QoL and 
mood 
 
Aspects of health-related QoL and mood improved 
following two weeks of daily tVNS (see Supplementary 
Table 9). For health-related QoL, scores for role 
 
 
Figure 7. LF/HF ratio values during visit 1 (A) and visit 2 (B) for each responder during baseline, tVNS and recovery. Dashed black line 
indicates the group mean. 
 
 
 
Figure 8. Baseline LF/HF ratio reduced after 2 weeks of daily 
tVNS in seven non-responders with ten showing an increase in 
baseline LF/HF ratio following the daily tVNS (indicated by the 
blue boxes). 
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limitations due to physical health significantly 
decreased between visits 1 and 2 (p = 0.026). 
Additionally, there was a trend for energy scores to 
increase following the two weeks of daily tVNS (p = 
0.058). For mood, self-reported tension (p = 0.015), 
depression (p = 0.035), vigour (p = 0.030) and mood 
disturbance (p = 0.006) all significantly improved 
between the two visits. There was also a trend for self-
reported confusion to be lower at visit 2 than at visit 1 
(p = 0.059).  
 
Linear regressions revealed that SF-36 energy scores 
during visit 1 significantly predicted change during visit 
2 (R2 = 0.280, p = 0.029): those with low energy scores 
at visit 1 reported greater increases at visit 2 (see Figure 
10).  
 
Furthermore, visit 1 POMS scores for tension (R2 = 
0.307, p = 0.014), depression (R2 = 0.475, p = 0.001), 
anger (R2 = 0.490, p = 0.001) and confusion (R2 = 
0.560, p < 0.001) significantly predicted scores at visit 
2: participants with high tension, depression, anger and 
confusion scores at visit 1 reported greater 
improvements at visit 2 than those with low scores (see 
Figure 11).  
 
Ease of falling asleep (R2 = 0.265, p = 0.024), how 
quickly it took participants to fall asleep (R2 = 0.380, p 
= 0.005), quality of sleep (R2 = 0.223, p = 0.041) and 
ease of waking up (R2 = 0.264, p = 0.024) in visit 1, 
significantly predicted change between the two visits. 
As depicted in Figure 12, those who experienced greater 
improvements in ease of falling asleep, time taken to 
fall asleep, quality of sleep and ease of waking up at 
visit 2 had lower values at visit 1. 
 
DISCUSSION 
 
Transcutaneous vagal nerve stimulation (tVNS) acutely 
administered to the tragus in healthy volunteers aged ≥  
 
 
Figure 10. LF/HF ratio values during visit 1 (A) and visit 2 (B) for each non-responder during baseline, tVNS and recovery. Dashed 
black line indicates the group mean. 
 
 
 
Figure 9. Visit 1 SF-36 energy score significantly predicted 
change at visit 2. 
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Figure 12. Visit 1 tension (A), depression (B), anger (C) and confusion (D) scores significantly predicted change at visit 2. 
 
 
 
Figure 11. Visit 1 ease of falling asleep (A), time taken to fall sleep (B), sleep quality (C) and ease of waking up (D) significantly 
predicted change at visit 2. 
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55 years was associated with improvements in 
spontaneous cardiac baroreflex sensitivity and HRV. 
Significantly, tVNS administered for 15 minutes every 
day for two weeks improved autonomic function and 
may improve some aspects of health-related QoL, mood 
and sleep. Intriguingly, findings consistently illustrated 
that individuals who have greater baseline sympathetic 
prevalence showed more pronounced shifts towards 
parasympathetic prevalence with tVNS, with daily 
tVNS for 2 weeks improving autonomic balance in 
some individuals. This means that tVNS administered 
daily for 2 weeks may help attenuate some of the 
autonomic and psychological changes that occur in 
ageing, expanding the period of healthy ageing. 
 
tVNS effects on autonomic function 
 
Positive effects of tVNS on autonomic function have 
been reported in non-patient groups. For instance, tVNS 
administered to the tragus significantly reduced 
sympathetic nerve activity in healthy participants [11] 
and boosted measures of parasympathetic activity, for 
example, spontaneous cardiac BRS [12], RMSSD [17], 
respiratory sinus arrhythmia (coupling between 
respiration and RR interval, [18]) and high frequency 
power spectrum [19]. Despite this evidence, there is 
little work examining the autonomic implications of 
administering tVNS in healthy older individuals who 
are undergoing age-associated shifts towards 
sympathetic prevalence. This study therefore examined 
the autonomic implications of tVNS in individuals aged 
≥ 55 years. We anticipated that a single session of tVNS 
would temporarily improve measures of autonomic 
function. We also hypothesized that daily 
administration of tVNS for two weeks would further 
enhance autonomic tone.  
 
Consistent with [12], a single session of tVNS was 
associated with greater increases in BRS compared to 
sham. Furthermore, tVNS promoted shifts towards 
parasympathetic prevalence in a larger cohort of 
individuals aged ≥ 55 years with daily tVNS improving 
resting vagal tone in some participants. BRS is a 
predictor of all-cause mortality [20]: depressed BRS (< 
3 ms/mmHg) was associated with reduced survival rates 
from cardiovascular death and all-cause mortality. This 
means that daily tVNS may be an effective tool for 
strengthening the relationship between changes in RR 
interval and SBP in individuals who have attenuated 
BRS, potentially reducing mortality and increasing life 
expectancy. 
 
Baseline LF/HF ratio (considered a measure of 
sympathovagal, or autonomic, balance) was a 
significant predictor of response to tVNS in all three 
studies: higher LF/HF ratio (greater sympathetic 
prevalence) was associated with greater decreases in 
LF/HF ratio (shifts towards parasympathetic 
prevalence). These patterns emerged in previous work 
[11], providing further support to potentially using 
LF/HF ratio as a tool for screening individuals who are 
likely to encounter greater autonomic benefits from 
tVNS. Such predictions could enable selection of 
optimal individuals for tVNS and may be particularly 
important considering the number of conditions that are 
characterized with enhanced sympathetic 
prevalence/autonomic imbalance, e.g. cardiovascular, 
pain, inflammatory and mental health conditions.  
Indeed, this would aid with developing a valid inclusion 
criteria for tVNS studies. Such criteria will need further 
development - in this study, baseline LF/HF ratios 
around 1.5 were associated with minimal changes (Δ = 
0) whereas those with baseline values > 1.5 were 
associated with decreases following tVNS. 
Interestingly, those who had low baseline LF/HF ratios 
(< 1.5) showed increases following tVNS, presumably 
due to already low sympathetic and high 
parasympathetic prevalence. It may therefore be 
possible to determine baseline LF/HF ratio thresholds 
which differentiate between response types. However, 
such thresholds may need to be ascertained with regard 
to recording and analysis conditions, since HRV can be 
determined using different algorithms with potentially 
variable outcomes regarding exact values.  
 
It is particularly interesting that the LF/HF ratio linear 
regressions reached statistical significance in study 3 
where the regression was stronger following two weeks 
of daily tVNS. Indeed, given the interaction effect 
between visit and condition for ∆ RR and a stronger 
linear regression for visit 2, perhaps daily tVNS for two 
weeks induced some kind of training effect. 
Furthermore, as some participants showed reductions in 
baseline LF/HF ratio between the two visits, it seems 
that daily use of tVNS confers autonomic benefits for 
some individuals. Indeed, benefits of tVNS delivered 
over long-time periods have been illustrated elsewhere, 
although not with regards to autonomic function. For 
instance, electrical stimulation of ABVN termination 
sites for 15 minutes per day for two weeks in patients 
with coronary artery disease decreased the need for 
vasodilator medication and improved exercise tolerance 
[21, 22]. In addition, in patients with paroxysmal atrial 
fibrillation (PAF) who received tragus stimulation 
(active) or ear lobe stimulation (sham) for 1 hour/day 
for 6 months, there was a 75-85% decrease in AF 
burden in the active compared to the sham stimulation 
[23]. Therefore, study 3 provides novel and timely data 
showcasing that daily tVNS can have profound 
autonomic benefits in individuals aged ≥ 55 years. Of 
course, future studies should explore the reproducibility 
of using baseline LF/HF ratio to determine response 
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type to tVNS. Additionally, it would be of interest to 
explore the autonomic effects of more long-term use of 
tVNS and optimum stimulation dosage. 
 
tVNS effects on quality of life, mood and sleep 
 
As well as conferring autonomic benefits, tVNS also 
appears to have positive effects on psychological health 
in patient groups. For instance, tVNS applied for two 
weeks (once or twice for 15 minutes per day, [24]) or 
for one month (twice for 30 minutes per day, [25]) in 
patients with depression significantly reduced 
depression scores. Furthermore, tVNS administered for 
four weeks significantly improved QoL and depression 
scores in patients with persistent postural-perceptual 
dizziness [26].  
 
Consistent with the above studies on psychological 
health, we found that daily tVNS for two weeks 
significantly improved measures of QoL, in particular, 
role limitations due to physical health. Furthermore, 
dimensions of mood including depression, tension, 
vigour and mood disturbance were all improved 
following two weeks of daily tVNS. These findings 
therefore suggest that daily tVNS may be an effective 
means of improving aspects of everyday life in this age 
group.  However, it should be acknowledged that since 
this was a single-arm study, it is possible that these self-
report measures could have been influenced by a 
placebo effect. Therefore, to further explore the effect 
of daily tVNS on subjective measures (such as QoL and 
mood), future studies should embrace designs and 
protocols which allow for an assessment of the 
contribution of placebo effects to improvements in such 
measures, perhaps via a significantly enlarged sample 
size. This could also be combined with other measures 
which assess performance on cognitive tasks. This 
would be particularly interesting, given that cognitive 
function declines in older age and studies have shown 
that tVNS can boost divergent thinking [27], associative 
memory in older individuals [28] and the recognition of 
emotions in faces when presented with whole faces [29] 
and just the eye region [30]. 
 
Sleep has also been shown to deteriorate with age [31] 
and could therefore potentially benefit from daily tVNS. 
Indeed, on returning for their second visit, some 
participants commented on improvements in aspects of 
their sleep. Indeed, participants who found that falling 
asleep took a long time and was difficult, had low sleep 
quality and had difficulties waking up in the morning, 
showed great improvements following two weeks of 
daily tVNS. This is an important finding and warrants 
further investigation employing a control group along 
with validated sleep questionnaires, such as the 
Pittsburgh Sleep Quality Index and polysomnography. 
Age-related conditions which could benefit from 
tVNS 
 
Normal ageing is associated with increases in 
sympathetic prevalence and/or decreases in vagal tone 
and overall variability [1, 2]. These ageing effects 
interact with gender, whereby the greater sympathetic 
prevalence in young males compared to young females 
disappears in older age [2]. In addition to normal 
ageing, shifts towards sympathetic prevalence may 
contribute to age-related conditions, for example, 
hypertension, heart failure and atrial fibrillation. 
Evidence suggests that tVNS could play a role in 
ameliorating these conditions. 
 
Electrical stimulation of ABVN termination sites for 
only 15 minutes per day for 14 days in patients with 
coronary artery disease decreased the need for 
vasodilator medication and improved exercise tolerance 
[21, 22]. Furthermore, tVNS reduced atrial fibrillation 
in patients with paroxysmal atrial fibrillation (PAF) and 
reduced plasma levels of the inflammatory cytokine 
TNFα [32], which is associated with chronic increases 
in inflammation with ageing [33]. Similar positive 
effects were observed when low-level tragus stimulation 
(LL-TS) was administered to canines [34]. Indeed, LL-
TS successfully reversed an increase in neural activity 
(in the anterior right ganglionated plexi) and a decrease 
in the window of vulnerability and effective refractory 
period that accompanied induced atrial fibrillation [34]. 
Therefore, tVNS administered to ABVN sites appears to 
temporarily improve symptoms associated with age-
related conditions, such as PAF and coronary artery 
disease. 
 
In addition to age-associated cardiovascular 
pathophysiology, tVNS may confer benefits in other 
age-related conditions. Also, tVNS reduced pain ratings 
in chronic pelvic pain due to endometriosis in females 
[35] and during sustained application of painful heat 
[36]. These findings are noteworthy given that ageing is 
associated with increases in pain [37]. tVNS may even 
be used as a non-invasive functional technique for the 
early diagnosis of Alzheimer’s disease and other 
neurodegenerative conditions [38] and aid with the 
progression of obesity and type 2 diabetes [39-42].  
 
Considering the ease of application and affordability of 
tVNS there is significant potential in prolonging the 
period of healthy ageing and attenuating symptoms 
associated with age-related conditions. Of course, 
considerable work exploring the optimum tVNS 
stimulation parameters (current, pulse width, pulse 
frequency), tVNS session duration (e.g. 15 minutes) and 
chronic paradigm (e.g. once daily for two weeks) for 
specific conditions/patient groups may be required. 
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Future studies should also carefully consider their study 
design, especially with respect to control groups. 
Indeed, it should be acknowledged that the single-arm 
design of studies 2 and 3 is a limitation. However, this 
design was adopted for two main reasons. Firstly, [11] 
and study 1 revealed tVNS was associated with greater 
autonomic balance compared to sham. Secondly, there 
are challenges with establishing a valid control for 
chronically administered tVNS. For instance, if the 
sham arm comprised of altering the internal workings of 
the machine so that it administered no electrical 
impulses but the machine still ‘looked’ active, 
participants might have realized they were receiving no 
stimulation (given that tVNS is perceptible). In which 
case, the sham would not have been able to explore the 
contribution of a placebo effect to changes in measures 
of autonomic function, health-related QoL, mood and 
sleep. An alternative sham could have entailed 
administering the stimulation to the earlobe. However, 
the assertion that the earlobe is not vagally innervated is 
based on one study [43] and there has recently been 
controversy about the anatomical location of the 
auricular vagus [44-46]. Due to these challenges, we 
decided to implement a single-arm design for studies 2 
and 3 where each participant acted as their own control. 
Future work could implement a wash-out period, which 
would also aid with ascertaining the time required for 
the effect of daily tVNS to diminish. This future work 
should also explore the extent to which the changes in 
the self-report measures were due to tVNS, a placebo 
effect or a participant bias. 
 
CONCLUSION 
 
For the first time, we have shown that age-related 
autonomic, QoL, mood and sleep changes may be 
improved with tVNS administered every day for two 
weeks. Importantly, the findings point to the influence 
of initial values in determining magnitude and direction 
of change following tVNS: high initial sympathetic 
prevalence, tension, depression, anger and confusion 
and low energy and sleep quality were associated with 
greater improvements. With further work, it may 
therefore be possible to identify which individuals will 
most benefit from daily tVNS in terms of their 
autonomic function and overall well-being. 
 
METHODS 
 
Ethical approval 
 
University of Leeds ethical approval was secured 
(Ethics Reference: BIOSCI 13-025) and the study 
conformed to the standards outlined in the Declaration 
of Helsinki. Informed written consent was obtained 
voluntarily by all research participants and their data 
were anonymised and stored securely according to the 
UK Data Protection Act (1998). Participants were 
informed that they could withdraw from the experiment 
at any time. 
 
Participants 
 
Participants were excluded if they had a history of 
cardiovascular disease, epilepsy or episodes of frequent 
fainting (syncope). Participants were asked to abstain 
from caffeine, alcohol, nicotine and strenuous exercise 
for a minimum of 12 hours prior to their visit. No 
female participants who participated were taking 
hormone replacement therapy (HRT). 
 
For study 1, 14 healthy volunteers aged 55 years or over 
were recruited (n = 9 males, mean age: 69.11 ± 1.52 
years). An additional 37 healthy participants aged 55 
years or over were recruited for study 2, resulting in a 
total sample size of 51 participants (n = 24 males, mean 
age: 65.20 ± 0.79 years). The daily tVNS study was 
conducted on 29 participants (study 3, n = 11 males, 
mean age range: 64.14 ± 0.89 years). 
 
Procedure 
 
All study visits were carried out in a quiet, temperature 
controlled (21 ± 2°C) human physiology study room at 
the University of Leeds between the hours of 09.00 and 
12.00. Participants reclined semi-supine on a couch for 
the duration of each experiment. 
 
Transcutaneous vagus nerve stimulation (tVNS) 
 
tVNS was performed using a TENS machine (V-TENS 
Plus, Body Clock Health Care Ltd, United Kingdom in 
studies 1 and 2 and EMS7500 Roscoe Medical in study 
3) with customised auricular electrode clips attached on 
the inner and outer surface of the tragus of the ear 
(Auricular Clips, Body Clock Health Care Ltd, UK). 
Participants wore the electrode clips throughout all 
three recordings (baseline, stimulation, recovery). tVNS 
was applied continuously for 15 minutes with a pulse 
width of 200 µs and pulse frequency of 30 Hz. 
Amplitude was adjusted to the level of sensory 
threshold (usually 2-4 mA) until the participants 
reported a ‘pin-prick’ or ‘tingling’ sensation. The 
stimulus was then turned down until the stimulus was 
borderline perceptible and comfortable. 
 
Study 1 procedure 
 
Study 1 examined the extent to which tVNS and sham 
stimulation impacted measures of autonomic function. 
Participants attended a ‘tVNS visit’ and a ‘sham visit’. 
Sham stimulation entailed positioning the surface 
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electrodes as per tVNS and informing participants that a 
different set of stimulation parameters would be tested 
involving a reduction in the current below the 
participant’s level of sensory perception. The electrode 
leads were then disconnected from the TENS machine 
without the participant’s knowledge. The order of the 
visits was randomized between participants. At the 
beginning of each visit, they completed a basic health 
questionnaire, physical activity level was assessed using 
the Godin Leisure Time Exercise Questionnaire [47] and 
height and weight obtained. Physiological equipment 
that continuously recorded HR, blood pressure (BP) and 
respiration were then attached and participants rested for 
10 minutes before recordings commenced. Three sets of 
recordings were obtained: 10 minute baseline, 15 minute 
stimulation and 10 minute recovery. The order of the 
recordings was identical for all participants. Figure 13 
summarises the procedure employed in study 1.  
 
Study 2 procedure 
 
Study 2 explored the effects of acute tVNS (i.e. a single 
15-minute session) on autonomic function in a larger 
group of individuals aged ≥ 55 years. The procedure 
was identical to that employed in study 1, with the 
exception that participants were not required to attend 
for a sham visit (rationale based on study 1 results). 
Figure 14 summarises the study 2 procedure.  
 
 
Figure 13. Procedure for study 1. 
 
 
 
Figure 14. Procedure for study 2. 
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Study 3 procedure 
 
Study 3 examined the effects of daily tVNS on 
autonomic function, QoL, mood and sleep in 29 healthy 
volunteers aged ≥ 55 years (Figure 15). The procedure 
was similar to that employed in study 1, with the 
exception that participants attended on a second 
occasion, exactly two weeks following their first visit 
for a second tVNS visit. In addition, participants 
completed the SF-36, POMS questionnaire (Profile of 
Mood States) and a sleep questionnaire at the beginning 
of each visit. At the end of their first visit, participants 
were provided with a tVNS machine to take home. They 
were trained in how to use the device and instructed to 
do a 15-minute session once daily for two weeks. A log 
sheet was provided so that participants could record 
device usage and any comments/observations following 
each session. 
 
Measurements 
 
In all three studies, HR, non-invasive BP and respiration 
were continuously recorded during the three recordings 
(baseline, tVNS, recovery). Non-invasive BP was 
recorded for the primary purpose of deriving BRS. In 
study 3, the SF-36 (measuring health-related QoL), 
Profile of Mood States (POMS) questionnaire 
(measuring mood) and sleep questionnaire (measuring 
sleep quality, ease of falling asleep and waking up, and 
sleep interruption) were completed by participants. 
Frequency-domain, time-domain and non-linear HRV 
and cardiac BRS were derived for the final five minutes 
of each recording and health-related QoL, mood and 
sleep scores were also calculated for study 3. For further 
information on the measurements obtained, please see 
the Methods Supplementary Section. 
 
Data analysis 
 
The final five minutes of each recording were analysed 
offline in LabChart 8 (AD Instruments). Frequency-
domain, time-domain and non-linear HRV were derived 
along with BRS. Change (Δ) between baseline and 
stimulation was calculated in all three studies. 
 
HRV variables 
 
Frequency-domain HRV 
Frequency-domain HRV parameters included: the low 
frequency (LF) component, detected at 0.04-0.15 Hz; 
the high frequency (HF) component, detected at 0.15-
0.40 Hz; total power (0.04-0.40 Hz) and normalised 
values for LF and HF power (nuLF and nuHF). The HF 
component has been associated with parasympathetic 
modulation of heart rate [48], whereas LF power 
reflects both parasympathetic and sympathetic 
 
 
Figure 15. Procedure for study 3. 
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modulation of heart rate [49]. The ratio of LF to HF 
power (LF/HF) was also calculated along with 
normalised LF/HF (nuLF/HF) where baseline values 
were set to 1. A decrease in LF/HF ratio suggests a shift 
in cardiac autonomic input towards either reduced 
sympathetic activity and/or increased vagal 
parasympathetic activity. 
 
Time-domain HRV 
Five time domain HRV variables were analysed: mean 
RR interval, Δ RR (difference between the longest and 
shortest RR intervals), SDRR (standard deviation of all 
RR intervals), RMSSD (the square root of the squared 
of differences between adjacent RR intervals) and 
pRR50 (percentage of number of pairs of adjacent RR 
intervals differing by more than 50 ms). SDRR reflects 
global autonomic regulation and is an estimate of all 
HRV [50]. RMSSD and pRR50, being mainly related to 
beat-to-beat variations, reflect parasympathetic output 
[50]. 
 
Non-linear HRV 
The Poincaré plot is a two-dimensional graphic 
representation of the correlation between consecutive 
RR intervals, in which each interval is plotted against 
the following interval. For quantitative analysis, an 
ellipse is fitted to the shape formed by the plot with the 
center determined by the average RR intervals. Two 
parameters were derived: SD1 and SD2. SD1 measures 
the standard deviation of the distances of the points to 
the diagonal y=x and SD2 measures the standard 
deviation of the distances of points to the line y=-x + 
RRm, where RRm is the average of RR intervals. SD1 
is an index of instantaneous recording of the variability 
of beat-to-beat and represents parasympathetic activity, 
while SD2 represents the variability of long and short 
term variability. SD1 and SD2 were normalised relative 
to heart rate by computing: (SD1 or SD2/RR 
interval)*1000. SD2/SD1 was also derived and 
represented the ratio between short and long term 
variations in RR intervals. The area of the ellipse, S, 
representing total variability in RR intervals was 
ascertained by calculating π*SD1*SD2. 
 
Cardiac baroreflex sensitivity (BRS) 
 
Cardiac BRS was assessed using the sequence method, 
in which ‘up’ and ‘down’ sequences were identified 
[51]. ‘Up’ sequences consisted of three or more 
consecutive cardiac cycles for which there was a 
sequential rise in both SBP (≥ 1 mmHg) and RR 
interval (≥ 2 ms). ‘Down’ sequences consisted of three 
or more cardiac cycles for which there was a sequential 
fall in SBP and RR interval. 
 
In Excel 2013, the RR interval was plotted against SBP 
for each sequence (r ≥ 0.85 acceptance level) and the 
average slope values for the ‘up’ and ‘down’ sequences 
were combined to get an average cardiac baroreflex 
slope. Values of cardiac BRS were accepted when the 
number of sequences was ≥3 for both up and down 
sequences. 
 
Statistical Analysis 
 
Statistical analysis was performed using SPSS (version 
25). Normality of distribution was tested using Shapiro-
Wilk. Two-tailed statistical tests were used in all 
instances with an alpha level of 0.05. All data are 
presented as group mean ± standard error of the mean 
(SEM) unless otherwise stated. 
 
The supplementary methods and materials section 
provides further information about the statistical tests 
performed. In brief, paired sample t-tests (or Wilcoxon 
signed-rank tests) explored differences between tVNS 
and sham (study 1) and following 14 days of tVNS 
(study 3). Repeated measure ANOVAs examined 
differences between recordings (study 2) and visits 
(study 3, two-way repeated measure ANOVAs). Linear 
regressions explored the extent to which baseline 
autonomic function significantly predicted response to a 
single session and daily use of tVNS. 
 
Abbreviations 
 
ABVN: auricular branch of the vagus nerve; BMI: body 
mass index; BP: blood pressure; BRS: baroreflex 
sensitivity; ECG: electrocardiogram; HF: high 
frequency power; HR: heart rate; HRT: hormone 
replacement therapy; HRV: heart rate variability; LF: 
low frequency power; LF/HF: ratio of low frequency to 
high frequency power; LL-TS: low-level tragus 
stimulation; nSD1: SD1 normalised relative to heart 
rate; nSD2: SD2 normalised relative to heart rate; 
nuHF: normalised high frequency power; nuLF: 
normalised low frequency power; PAF: paroxysmal 
atrial fibrillation; POMS: profile of mood states; 
pRR50: percentage of number of pairs of adjacent RR 
intervals differing by more than 50 ms; QoL: quality of 
life; RR interval: interval between adjacent R peaks; 
RMSSD: square root of the squared of differences 
between adjacent RR intervals; S: area of the ellipse of 
the Poincaré plot; SBP: systolic blood pressure; SD1: 
standard deviation of points perpendicular to the axis of 
line-of-identity; SD2: standard deviation of points along 
the axis of line-of-identity; SD2/SD1: ratio of SD2 to 
SD1; SDRR: standard deviation of all RR intervals; 
SEM: standard error of the mean; SF-36: questionnaire 
providing a measure of health-related quality of life; 
TENS: transcutaneous electrical nerve stimulation; 
tVNS: transcutaneous vagal nerve stimulation; VNS: 
vagal nerve stimulation. 
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SUPPLEMENTARY MATERIAL 
 
 
Supplementary Methods 
 
Measurements 
 
Heart rate was derived from electrocardiogram (ECG) 
recorded by 3 Ag-AgCl surface electrodes on the chest 
sampled at 2 kHz and continuous blood pressure was 
recorded via finger pulse plethysmography (Finometer; 
Finapres Medical System, Netherlands) sampled at 400 
Hz in LabChart 8 (AD Instruments). Continuous blood 
pressure recordings were obtained in order to derive 
cardiac baroreflex sensitivity (BRS). Respiration was 
recorded via a strain-gauge transducer (Pneumotrace, 
UFI, CA, USA) placed around the chest and sampled at 
0.4 kHz (in LabChart 8). Participants were allowed to 
breathe spontaneously but their respiration rate monitored 
to ensure there were no major deviations (> ±2 breaths 
per minute from baseline value) and a minimum 
respiration rate of ≥ 10 breaths per minute was met. One 
participant in studies 2 and 3 had a respiration rate < 10 
breaths per minute and was subsequently excluded from 
all further analyses. 
 
In study 3, two questionnaires were completed by 
participants at the beginning of each visit: SF-36 and 
Profile of Mood States (POMS). The SF-36 provides an 
indication of health-related QoL from which scores on 
different aspects of QoL can be derived e.g. physical 
functioning, role limitations due to physical and 
emotional health, energy, emotional well-being, social 
functioning, pain, and general health scores. The POMS 
questionnaire was used to gain an indication of how 
specific aspects of mood may change as a result of the 
fortnight of daily tVNS e.g. depression, tension, anger, 
fatigue, confusion, vigour and mood disturbance). 
 
Statistical Analysis 
 
Study 1 
To assess the extent to which autonomic function (HRV 
and BRS) was significantly influenced by tVNS and sham 
stimulation, paired sample t-tests (or Wilcoxon signed-
rank tests) were performed on change (Δ) between 
baseline and stimulation. Linear regressions examined 
whether baseline measures of autonomic function 
significantly predicted response (change (Δ) between 
baseline and stimulation).  
 
Study 2 
To explore the extent to which tVNS significantly 
influenced measures of autonomic function in a larger 
sample of individuals aged ≥ 55 years, one-way repeated 
measure ANOVAS with Bonferroni pairwise 
comparisons were conducted. For non-normally 
distributed data, Friedman tests with Wilcoxon signed-
rank post-hoc tests were performed. Linear regressions 
explored the extent to which baseline measures of 
autonomic function significantly predicted response (Δ) 
to tVNS. To explore differences in baseline measures of 
autonomic function, independent sample t-tests (or Mann-
Whitney U tests) were performed. 
 
Study 3 
Paired sample t-tests (or Wilcoxon signed-rank tests) 
examined the extent to which baseline autonomic tone, 
health-related QoL, mood and sleep changed following 
the fortnight of daily home-use tVNS. Two-way repeated 
measure ANOVAs explored differences in measures of 
autonomic function between the two visits and between 
the three conditions. Linear regressions assessed whether 
baseline autonomic tone, health-related QoL, mood and 
sleep in visit 1 predicted change to visit 2 baseline to 
tVNS. Independent sample t-tests (or Mann-Whitney U 
tests) explored differences between responders and non-
responders.  
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Supplementary Tables 
 
Study 1 
 
Supplementary Table 1. Summary of characteristics of the final sample of study 1. 
Final sample size (n) 14 
Gender (frequency of males) 9 
Age (yrs.) 69.14 (1.82) 
BMI (kg/m2) 25.83 (1.05) 
Baseline SBP (mmHg) 121.07 (3.87) 
Baseline DBP (mmHg) 74.29 (1.80) 
Baseline MAP (mmHg) 89.88 (2.42) 
 
 
 
 
Study 2 
 
Supplementary Table 2. Summary of characteristics of the final sample of study 2. 
Final sample size (n) 48 
Gender (frequency of males) 22 
Age (yrs.) 65.28 (0.85) 
BMI (kg/m2) 27.13 (0.79) 
Baseline SBP (mmHg) 123.63 (2.44) 
Baseline DBP (mmHg) 79.09 (1.42) 
Baseline MAP (mmHg) 93.94 (1.69) 
 
 
 
Supplementary Table 3. Statistically significant differences between the three recordings (baseline, tVNS, 
recovery) transpired. Reported p-values are from the one-way ANOVAs/Friedman tests. * = significantly 
different to baseline (post-hoc tests). Data presented as the mean ± 1 SEM. 
 Baseline tVNS Recovery p-value 
Total power (ms2) 1161 (145) * 1726 (255) * 2011 (259) 0.007 
LF power (ms2) 284 (51) * 391 (75) * 460 (61) 0.009 
HF power (ms2) 351 (68) 388 (69) * 448 (85) 0.001 
nuLF 51 (3) 52 (3) 55 (3) n.s 
nuHF 50 (3) 49 (2) 46 (3) n.s 
LF/HF ratio 1.58 (0.21) 1.40 (0.16) 1.96 (0.32) n.s 
Mean RR interval (ms) 963 (20) * 1001 (21) * 1009 (21) < 0.001 
Δ RR (ms) 225 (16) * 249 (15) 244 (14) < 0.001 
SDRR (ms) 35 (2) *  42 (3) * 42 (3) < 0.001 
RMSSD (ms) 28 (3) * 31 (3) 31 (3) < 0.001 
pRR50 (%) 9 (2) * 10 (2) 10 (2) 0.003 
SD1 (ms) 20 (2) * 22 (2) 22 (2) < 0.001 
SD2 (ms) 44 (2) *  54 (4) * 55 (3) < 0.001 
nSD1 20 (2) 21 (2) 21 (2) n.s 
nSD2 46 (2) * 53 (3) * 55 (3) 0.006 
SD2/SD1 2.83 (0.21) 2.82 (0.18) 2.93 (0.17) n.s 
S (ms2) 3258 (507) * 4586 (794) * 4429 (660) < 0.001 
BRS (ms/mmHg) 7.22 (0.60) * 8.83 (0.67) 8.29 (0.67) 0.006 
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Supplementary Table 4. Summary of statistically significant differences in baseline measures of autonomic 
function between responders and non-responders. Data presented as the mean ± 1 SEM. 
 Responders (n = 16) Non-responders (n = 32) p-value 
HF power (ms2) 179.98 (59) 436.47 (95) 0.013 
nuLF 65.88 (4) 43.94 (4) 0.001 
nuHF 35.43 (4) 56.93 (4) 0.001 
LF/HF ratio 2.70 (0.42) 1.09 (0.17) < 0.001 
RMSSD (ms) 22.11 (5) 31.39 (3) 0.029 
SD1 (ms) 15.66 (3) 22.17 (2) 0.029 
nSD1 16.67(3) 22.01 (2) 0.029 
SD2/SD1 3.53 (0.46) 2.48 (0.20) 0.047 
S (ms2) 2548.37 (927) 3612.35 (604) 0.034 
BRS (ms/mmHg) 5.15 (0.93) 8.32 (0.71) 0.011 
 
 
 
Supplementary Table 5. Demographic characteristics of responders and non-responders: there were no 
statistically significant differences between responders and non-responders. 
 Responders (n = 16) Non-responders (n = 32) p-value 
Gender (male) 6 16 n.s 
Age (yrs.) 66.63 (1.87) 64.56 (0.84) n.s 
BMI (kg/m2) 27.51 (0.98) 26.95 (1.08) n.s 
 
 
 
 
Study 3 
 
Supplementary Table 6. Measures of vagal tone were significantly higher during visit 2 compared to visit 1. 
Reported p-values are from the significant main effects of visit. Data presented as the mean ± 1 SEM. 
 Visit 1 Visit 2 p-value 
Total power (ms2) 1618 (264) 2202 (389) 0.046 
HF power (ms2) 443 (107) 676 (146) 0.051 
SDRR (ms) 40 (4) 45 (4) 0.024 
RMSSD (ms) 30 (4) 36 (5) 0.016 
pRR50 (%) 11 (3) 15 (4) 0.010 
SD1 (ms) 21 (3) 26 (3) 0.016 
nSD1 20 (2) 25 (3) 0.022 
SD2 (ms) 52 (4) 57 (5) 0.035 
S (ms2) 4189 (830) 5828 (1099) 0.012 
 
 
Supplementary Table 7. Measures of overall variability significantly differed between the three recordings 
(baseline, tVNS, recovery). Reported p-values are from the significant main effects of recording. * = significantly 
different to baseline. Data presented as the mean ± 1 SEM. 
 Baseline tVNS Recovery p-value 
Total power (ms2) 1345 (205) * 2216 (395) * 2169 (400) 0.010 
LF power (ms2) 325 (54) * 529 (109) 544 (116) 0.039 
SDRR (ms) 36 (3) * 47 (5) * 44 (4) < 0.001 
SD2 (ms) 45 (3) * 61 (6) * 57 (5) < 0.001 
S (ms2) 3814 (731) * 5876 (1244) 5336 (1035) 0.026 
Mean RR interval (ms) 970 (32) * 1011 (33) * 1010 (33) < 0.001 
nSD2 46 (3) * 59 (5) * 56 (4) < 0.001 
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Supplementary Table 8. Summary of demographic characteristics and visit 1 baseline autonomic measures for 
responders and non-responders. Data are presented as the mean ± 1 SEM. 
  Responders (n = 9) Non-responders (n = 17) p-value 
Demographic 
characteristics 
Gender (male) 3 6 n.s 
Age (yrs.) 63.78 (1.52) 64.29 (1.29) n.s 
BMI (kg/m2) 28.12 (1.70) 28.05 (1.73) n.s 
Visit 1 baseline 
autonomic 
measures 
HF power (ms2) 197.23 (99) 528.75 (166) 0.034 
SDRR (ms) 26.45 (4) 39.21 (4) 0.038 
SD2 (ms) 33.92 (4) 49.65 (18) 0.028 
nSD1 14.57 (4) 22.83 (3) 0.039 
nSD2 36.22 (4) 51.08 (4) 0.036 
S (ms2) 1762.81 (611) 4128.50 (1004) 0.039 
BRS (ms/mmHg) 4.35 (1.19) 8.24 (1.11) 0.036 
 
 
 
Supplementary Table 9. Summary of changes in health-related QoL and mood between visits 1 and 2. Data 
presented as the mean ± 1 SEM. 
  Visit 1 Visit 2 p-value 
SF-36 Role limitations due to physical health score 84 (7) 69 (11) 0.026 
Energy score 61 (5) 67 (4) 0.058 
POMS Tension score 7 (1) 4 (1) 0.015 
Depression score 6 (2) 3 (1) 0.035 
Vigour score 19 (1) 21 (1) 0.030 
Mood disturbance score 8 (5) -2 (5) 0.006 
Confusion score 6 (1) 5 (1) 0.059 
 
 
